NCT00735345 - Chemotherapy Induction and Chemoradiotherapy in Patients With Esophageal Carcinoma | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

August 31, 2008

Primary Completion Date

December 31, 2012

Study Completion Date

December 31, 2012

Conditions

Esophageal Cancer

Interventions

DRUG

5-FU

750 mg/m2/d C.I. i.v.d1-5, d29-33 and 300 mg/m2/d C.I. i.v. on the days of radiotherapy

DRUG

Cisplatin

15 mg/m2/d i.v. d1-5, d29-33

DRUG

Taxotere

75 mg/m2/d i.v. d1 and d29, 15 mg/m2/d i.v. on d57, d64, d71 and d78

BIOLOGICAL

Cetuximab

Cetuximab: 400 mg/m2 i.v. d1; 250mg/m2 weekly d8 through d85

RADIATION

Radiation during chemoradio-immunotherapy

39.6 Gy total dose

Trial Locations (7)

Landeskrankenhaus Feldkirch, Feldkirch

Universitätsklinikum Graz, Graz

Universitätsklinik Innsbruck, Innsbruck

A.ö. Landeskrankenhaus Leoben, Leoben

Krankenhaus Barmherzige Brueder St. Veit a.d. Glan, Saint Veit/ Glan

Universitaetsklinik f. Innere Medizin III, Salzburg

Klinikum Kreuzschwestern Wels GmbH, Wels